Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-115
SponsorNational Human Genome Research Institute (NHGRI)

About this trial

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.

The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following:

1. X-rays 2. Consultations with specialists 3. DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome. 4. Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness) 5. Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm.

Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options.

Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness).

Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above.

Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future....

Eligibility criteria

Qualifiers

Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);

Regardless of gender, at least one month of age;

A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and

Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

5,000 Participants
are grouped into 3 trial groups

Sponsors and collaborators

National Human Genome Research Institute (NHGRI)

Lead sponsor

University of Massachusetts, Worcester

Collaborator

Duke University

Collaborator

Merck Sharp & Dohme LLC

Collaborator